# US 2026/0083816 A1 · Methods of treating cancer by targeting drivers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083816 A1
- Document ID: US20260083816A1
- Status: Published application
- Kind: A1
- Application number: 18/923,976
- Filed: 2024-10-23
- Published: 2026-03-26
- Earliest claimed: 2022-04-25
- Assignees: Delta Next-Gene, LLC
- Applicants: Delta Next-Gene, LLC
- Inventors: Erlinda M. Gordon; Fredrick L. Hall
- Web page: https://patentgrep.com/patent/US20260083816A1

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/4196: 1,2,4-Triazoles
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61P 35/00: Antineoplastic agents
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides methods of using combination therapies to treat cancer. These methods are based on inhibiting cyclin proteins along with proteins along the Cyclin Axis. Thus, a method of the disclosure may generally be practiced by administering to an individual having cancer a cytocidal inhibitor of cyclin, along with a therapeutic agent that targets other molecules involved in pathways that promote cyclin activity. These therapeutic agents may target biomarkers on the surface of a cancer cell and that promote cyclin activity as well as intracellular proteins involved in pathways that affect, or are affected by, cyclin activity.

## Claims

### Claim 1

A method of treating a cancer in an individual, wherein the cancer cells express at least one biomarker that is part of a biochemical pathway that promotes cyclin protein activity, the method comprising administering to the individual:
a. a first therapeutic agent comprising a tumor-targeted vector encoding a cytocidal inhibitor of cyclin 1; and,
b. a second therapeutic agent that acts on the biochemical pathway that increase cyclin protein activity;
wherein the second therapeutic agent inhibits the biochemical pathway.

### Claim 2 (depends on 1)

The method of claim 1, wherein the second therapeutic agent binds the at least one biomarker.

### Claim 3 (depends on 1, 2)

The method of claim 1or 2, wherein the biochemical pathway comprises an oncogenic receptor-mediated signaling pathway.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the biochemical pathway comprises a tumor suppressor pathway.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein the biochemical pathway comprises a stem cell renewal or differentiation pathway.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the at least one biomarker is selected from the group consisting of estrogen receptor (ER), progesterone receptor (PR) human epidermal growth factor 2 (HER2), androgen receptor (AR), fibroblast growth factor 13 (FGF13), FGF14, FGF19, phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA), NOTCH3, EMSY, tumor protein 53 (TP52), and bromodomain-containing protein 4 (BRD4).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the second therapeutic agent binds HER2.

### Claim 8 (depends on 7)

The method of claim 7, wherein the second therapeutic agent inhibits HER2 heterodimerization.

### Claim 9 (depends on 7, 8)

The method of claim 7 or 8, wherein the second therapeutic agent inhibits the P13K/AKT signaling pathway.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the second therapeutic agent comprises a monoclonal antibody that specifically binds HER2.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the second therapeutic agent comprises Trastuzumab or Pertuzumab.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the cancer cells express at least two or more biomarkers, each of which is part of a unique biochemical pathway that promotes cyclin protein activity, wherein the method comprises administering to the individual a third therapeutic agent that inhibits a biochemical pathway, and wherein the second and third therapeutic agents inhibit different biochemical pathways.

### Claim 13 (depends on 12)

The method of claim 12, wherein the third therapeutic agent inhibits signaling by the ER.

### Claim 14 (depends on 13)

The method of claim 13, wherein the third therapeutic agent inhibits the production of estrogen.

### Claim 15 (depends on 13, 14)

The method of claim 13 or 14, wherein the third therapeutic agent is an aromatase inhibitor.

### Claim 16 (depends on 12, 13, 14, 15)

The method of any one of claims 12-15, wherein the third therapeutic agent is Letrozole.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claim 1-16, wherein the tumor-targeted vector is DeltaRex-G or DeltaRex-GT.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claim 1-17, wherein the cancer in the individual includes a breast cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the individual is a post-menopausal woman.

### Claim 20 (depends on 18, 19)

The method of claim 18 or 19, wherein the breast cancer is an early-stage triple receptor positive invasive breast cancer.
